InvestorsHub Logo
Followers 3
Posts 299
Boards Moderated 0
Alias Born 12/21/2022

Re: Tartiaboy post# 436

Friday, 08/11/2023 2:59:42 PM

Friday, August 11, 2023 2:59:42 PM

Post# of 581
Something is wrong with their mono arm of APTIVATE trial. Only 1 response in 7 patients (14%, and they didn't say whether it is a PR or CR) is not what you would expect based on their dose escalation part where CRc rate with 80 mg dose was 30%. Looks like that as a single agent Tusp has no chance. No other choice but to run a combo. As for combo, they said it will be a randomized trial. It means, they will have a control arm. Not sure what drug is appropriate as control.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News